Peer-reviewed veterinary case report
Cyclophosphamide treatment for cats with relapsed low-grade
By Kim, Changseok et al.·Published in Journal of feline medicine and surgery·2021·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cyclophosphamide rescue therapy for relapsed low-grade alimentary lymphoma after chlorambucil treatment in cats.
- Species:
- cat
Plain-English summary
A group of cats with relapsed low-grade alimentary lymphoma (a type of cancer affecting the intestines) were treated with cyclophosphamide after their initial treatment with chlorambucil didn't work. Out of 20 cats, 18 showed significant improvement, with their symptoms disappearing for an average of about 239 days. The cats lived for a median of over 3 years after starting the cyclophosphamide treatment, and the side effects were mostly mild and temporary. This suggests that cyclophosphamide can be a safe and effective option for cats who need a second chance against this cancer.
People also search for: cat lymphoma treatment · cyclophosphamide for cats · relapsed lymphoma in cats · cat cancer survival rates
Abstract
OBJECTIVES: The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment. METHODS: The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described. RESULTS: Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs. CONCLUSIONS AND RELEVANCE: Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33645321/